Agios, iNovacia announce new collaboration
STOCKHOLM, Sweden—iNovacia AB has announced a high-throughput screening collaboration with Cambridge, Mass.-based Agios Pharmaceuticals, a company focusing on cancer metabolism. Per the terms of the agreement, iNovacia will provide small-molecule lead generation services for the collaboration in addition to identifying modulators of pharmaceutical targets of interest to Agios through use of iNovacia's proprietary screening library. Financial details for the collaboration were not disclosed.
"We have had successful screening projects with Agios in the past and we are now proud to be able to extend this relationship," Dr. Thomas Olin, CEO of iNovacia, said in a press release. "We are pleased that Agios and other U.S. and European companies continue to appreciate the value of our premium screening operations and proprietary screening library as a means to generate high-quality chemistry starting points."